The development of novel and proprietary stem cell technologies creates new hope for treating, and in some cases, perhaps even curing, human diseases like diabetes, Alzheimer’s, Parkinson’s, inflammatory disorders, osteoarthritis and damaged cartilage.
StemBioSys Inc.® is identifying promising clinical applications as well as collaborators to further develop and license stem cell technologies for research, pharmaceutical and clinical use.
We are currently focused on scale-up activities for our patented core technology, CELLvo™ Matrix and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology.
We have entered into an agreement pursuant to which BioBridge Global has constructed a cGMP compliant space of approximately 1,000 square feet. This space will be operated exclusively by StemBioSys for the production of its various CELLvo™ platform products.
University of Texas Health Science Center at San Antonio
The company’s scientific founder, and co-inventor on the licensed technology, Dr. Xiao-Dong Chen, is a Professor at the University and continues his research in stem cell and matrix biology and serves as a consultant for the company.
University of Texas at San Antonio
The company has contracted with the laboratories of Dr. John McCarrey, Director, San Antonio Cellular Therapeutics Institute, to perform various characterization and competitive product analyses for the company.
Massachusetts Institute of Technology
StemBioSys has entered into a sponsored research agreement with MIT and the laboratories of Robert Langer and Dan Anderson pursuant to which we will collaborate to gain insights into the mechanism of action of the company’s bone marrow stromal cell derived extracellular matrix in the isolation and expansion of human stem cells.